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CI = confidence interval; CK = creatine kinase; ECG = electrocardiography; FRISC = Fragmin during Instability in Coronary Artery Disease;
GUSTO = Global Utilisation of Streptokinase and tPA for Occluded Coronary Arteries; MI = myocardial infarction; MONICA = Monitoring Cardio-
vascular Disease study; OR = odds ratio; RR = relative risk; TIMI = Thrombolysis in Myocardial Infarction.
Available online http://cvm.controlled-trials.com/content/2/2/075
Introduction
Ischaemic heart disease comprises clinical conditions that
range from silent ischaemia to acute MI. Along with the
patient history, physical examination and electrocardiogra-
phy, measurement of biochemical markers is important in
assessing ischaemic heart disease. The ‘gold standard’ in
detecting myocardial necrosis has been an elevated level of
CK-MB (the cardiac-specific isoform of CK). This measure
satisfies the criteria for a diagnosis of MI (Table 1), as pro-
posed by the World Health Organization and later extended
for the Monitoring Cardiovascular Disease (MONICA) study
[1]. New cardiac markers, however, with superior specificity
and sensitivity to detect myocardial damage and the poten-
tial to estimate the prognosis of patients with ischaemic
myocardial necrosis, have challenged the diagnostic ability
of CK-MB. Furthermore, elevated CK-MB may not detect all
myocardial necrosis, because autopsies of patients who
died suddenly after severe or silent episodes of ischaemia
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Abstract
During the past decade considerable research has been conducted into the use of cardiac troponins,
their diagnostic capability and their potential to allow risk stratification in patients with acute chest pain.
Determination of risk in patients with suspected myocardial ischaemia is known to be as important as
retrospective confirmation of a diagnosis of myocardial infarction (MI). Therefore, creatine kinase
(CK)-MB – the former ‘gold standard’ in detecting myocardial necrosis – has been supplanted by new,
more accurate biomarkers. Measurement of cardiac troponin levels constitute a substantial determinant
in assessment of ischaemic heart disease, the presentations of which range from silent ischaemia to
acute MI. Under these conditions, troponin release is regarded as surrogate marker of thrombus
formation and peripheral embolization, and therefore new therapeutic strategies are focusing on potent
antithrombotic regimens to improve long-term outcomes. Although elevated troponin levels are highly
sensitive and specific indicators of myocardial damage, they are not always reflective of acute
ischaemic coronary artery disease; other processes have been identified that cause elevations in these
biomarkers. However, because prognosis appears to be related to the presence of troponins
regardless of the mechanism of myocardial damage, clinicians increasingly rely on troponin assays
when formulating individual therapeutic plans.
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have shown micronecrosis that was not reflected in routine
enzyme measures [2,3]. In addition, myocardial biopsies
taken during coronary artery bypass surgery in patients with
unstable angina have shown the presence of platelet aggre-
gates in small coronary vessels, with associated myocardial
necrosis [4].
New cardiac markers, such as troponins T, I and C, are
subunits of the thin filament-associated troponin–
tropomyosin complex, which is involved in regulating
muscle contraction. Genetic differences in cardiac and
skeletal muscle tissue have allowed development of mono-
clonal antibodies that are specific for release of cardiac
troponins T and I during myocardial injury [5,6]. Sporadic
reports [7,8] confirmed the ability of troponins to identify
micronecrotic pathology, despite exclusion of MI on con-
ventional grounds. Accordingly the new definition of MI
reported in September 2000 [9] introduced cardiac tro-
ponins into daily routine clinical practice, allowing for
highly accurate, sensitive and specific determination of
myocardial injury (Table 2). Moreover troponin measure-
ment is recommended in all patients with chest discomfort
that is consistent with an acute coronary syndrome [10].
The present review focuses on the potential of troponin
measurement to identify myocardial damage of any origin,
and the resulting diagnostic and therapeutic implications.
Characteristics of troponin release
Biochemical markers provide evidence of cell degradation,
which forms the rationale for diagnosis of a disease using
such markers; that is, detection of intracellular constituents
that are released into the blood (when the cell ruptures or
loses membrane integrity) allows identification of damaged
target tissue. Changes in serum concentration of these
markers are primarily determined by their molecular masses
and intracellular compartmentalization (Table 3).
CK and CK-MB exhibit a release pattern during MI that is
characteristic of a functionally unbound, cytosolic protein,
which is strongly dependent on perfusion in the infarct
zone [11]. In contrast, the cytosolic pool has been esti-
mated at 6% for troponin T and 3% for troponin I, resulting
in release kinetics that are typical of both structurally bound
and cytosolic molecules [12,13]. In cases of slow disinte-
gration of myofibrils, the ‘early’ cytosolic pool, combined
with the features of a bound myofibrillar protein, results in a
continuous release of troponin to a diagnostic threshold
that is strongly associated with adverse outcomes. CK-MB
is less abundant in the myocardium on a weight basis (with
small amounts normally present in the circulation), but is
cleared more rapidly than troponin T or I. During repeated
episodes of minor myocardial necrosis, CK-MB may be ele-
vated at each episode, but the increase is blunted by the
baseline amount present and by the rapid clearance of the
marker. In contrast, troponins have a negligible baseline
value and are cleared much more slowly, and therefore
they accumulate in the circulation (Fig. 1). This may partly
explain why some patients with acute coronary syndromes
have elevated troponin values – caused by superimposing
recurrent microinfarction events – but normal CK-MB at
presentation. However, release of troponins is indicative of
myocardial necrosis, but is not synonymous with an
ischaemic mechanism of the injury. Therefore, an elevated
troponin value in the absence of clinical evidence of
ischaemia should initiate a search for other causes of
myocardial damage. Table 4 summarizes possible causes
of elevation of troponins in blood.
Troponin assays
Troponin assays have evolved during the past decade,
and the latest rapid assays have provided emergency
room physicians with new diagnostic approaches [14].
‘Point-of-care’ assays can be performed without sophisti-
cated equipment, even by paramedics [15].
Table 1
World Health Organization criteria* for diagnosis of definite acute MI, possible acute MI or old MI
Type of evidence Criteria
History The history is typical if severe, prolonged chest pain is present. Sometimes the history is atypical, and the pain may 
be mild or even absent, or other symptoms may be predominant
Electrocardiography (ECG) Unequivocal changes in ECG are the development of abnormal, persistent Q or QS waves, and evolving injury 
current lasting longer than 1 day. When the ECG shows these unequivocal changes, the diagnosis may be made 
on the basis of ECG alone. In other cases the ECG may show equivocal changes, consisting of a stationary injury 
current, a symmetrical inversion of the T-wave, a pathological Q-wave in a single ECG record, or conduction 
disturbances
Serum enzymes Unequivocal changes consist of serial change, or initial rise and subsequent fall of the serum level. The change 
must be properly related to the particular enzyme, and to the delay time between onset of symptoms and blood 
sampling. Elevation in cardio-specific isoenzymes is also considered unequivocal change. Equivocal change 
consists of an enzyme pattern in which an initially elevated level is not accompanied by a subsequent fall – the 
curve of enzyme activity is not obtained
*Revised 1994 for the MONICA study [1].c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
The first enzyme-linked immunosorbent assay for troponin
T measurement was produced in 1989, with an assay cut-
off of 0.5 ng/ml and a turnaround time of 90 min [16]. The
most recent version is the Elecsys® third-generation assay
(Roche Diagnostics Corporation, Indianapolis, USA). This
assay uses recombinant human cardiac troponin as the
standard. It has improved precision, particularly at the low
end of the measuring range, with an analytical sensitivity of
below 0.025 ng/ml and a diagnostic cutoff of 0.1 ng/ml
[17]. Only one manufacturer provides a troponin T assay,
whereas various available assays may be used to measure
troponin I, using different antibodies that are directed
against different epitopes [18–24]. Because of the lack of
standardization in troponin I assays, up to 10-fold differ-
ences have been reported in absolute concentrations, at
cutoffs that range widely. The absence of a standardized
discriminator led to investigators using either the cutoff
recommended for the diagnosis of MI, the limit of assay
detection, or their own discriminators generated from ret-
rospective analysis of selected patient cohorts. Thus,
attention must be given to the assay used when interpret-
ing the data and the results of troponin I measurements.
Diagnostic value of troponins
Compared with CK-MB, the former ‘gold standard’ in diag-
nosing MI, troponin measurement offers substantially
better sensitivity for the detection of myocardial injury.
Release kinetics of troponins T and I are similar; both are
released within 4–12 h after myocardial necrosis, with a
Available online http://cvm.controlled-trials.com/content/2/2/075
Table 2
Definition of MI
Criteria for acute, evolving or recent MI
1 Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of 
the following:
• Ischaemic symptoms
• Development of pathologic Q-waves on electrocardiography
• Electrocardiography changes indicative of ischaemia (ST-segment elevation or depression)
• Coronary artery intervention
2 Pathologic findings of an acute MI
Criteria for established MI
1 Development of new pathologic Q-waves on serial electrocardiographs. The patient may or may not remember previous symptoms. 
Biochemical markers of myocardial necrosis may have normalized, depending on the length of time that has passed since the infarct developed
2 Pathologic findings of a healed or healing MI
Data from the European Society of Cardiology/American College of Cardiology consensus document [9].
Table 3
Characteristics of biochemical markers in acute MI
Molecular weight Hours to first increase 
Marker Localization (Da) after infarction Mean hours to peak Return to baseline (days)
CK-MB Cytosolic 86,000 3–10 10–24 ~3
Troponin T 6% Cytosolic 37,000 4–12 12–48 5–15
Troponin I 3% Cytosolic 24,000 4–12 10–24 5–10
Figure 1
Summation model. Temporal release of cardiac markers CK-MB and
troponins during repetitive episodes of ischaemia causing myocardial
necroses in the setting of an acute coronary syndrome. Compared with
the release and clearance of CK-MB 48–72 h after each episode
(indicated as 1st, 2nd and 3rd), troponin release is cumulative.peak value 12–48 h from symptom onset (Table 3),
depending on the duration of ischaemia and reperfusion.
Use of troponin T for noninvasive assessment of coronary
artery reperfusion after successful thrombolysis has been
described [12,25]; troponin T exhibited a typical biphasic
release, which is not seen with troponin I. Katus et al [26]
found 100% sensitivity and 93% specificity for a first-gen-
eration troponin T assay in 388 patients with MI.
Although the cardiac specificity of troponin T has been
questioned, particularly in patients with renal failure [27], a
recent immunohistochemical study [28] established that
troponin T isoforms expressed in renal diseased skeletal
muscle are not detected by the second- and third-genera-
tion troponin T assays. With regard to sensitivity, a meta-
analysis [29] showed that troponin T had a clinical
sensitivity of 98.2% (95% confidence interval [CI]
97–99%) for diagnosis of MI within 12 h after symptom
onset, which is similar to the 96.8% (95% CI 95–98%)
sensitivity of CK-MB. Specificity, however, was signifi-
cantly greater for CK-MB than for troponin T (89.6%
versus 68.8%; P < 0.001), because patients with minor
myocardial injury also had positive troponin T results.
However, it has also been shown [30–32] that troponin
sampling early after symptom onset (<4 h) results in a
sensitivity of only 33–49%. More recent studies [20,33],
which took the known delay in release into consideration
when defining the sampling pattern, described diagnostic
sensitivities of 77–100% for detection of MI more than 6 h
after onset of pain. Thus, in order to achieve optimal sensi-
tivity, serial sampling at least 12 h after symptom onset is
recommended.
Prognostic value of troponins
Acute coronary syndromes
In patients with chest pain at rest but without ST-segment
elevation, it is difficult to distinguish unstable angina from
MI, either clinically or angiographically [34]. However, the
extent of myocardial necrosis is an important predictor of
prognosis [35], and therefore early identification of
patients who are at high risk for an adverse outcome is as
important as confirming a diagnosis of MI.
In 1992, the prognostic value of troponin T was shown
convincingly [36]. Patients with class III unstable angina
(Braunwald classification) with elevated troponin T levels
had a heightened risk for major cardiac events during and
after hospitalization, as compared with troponin T-negative
patients (15% versus 1.9% for in-hospital death or MI;
P = 0.003).
The risk for nonfatal MI or death over different intervals after
an index event was addressed in several studies of patients
with unstable angina. Event rates for troponin T-positive
patients were significantly higher, confirming that these
patients represent a high-risk subset of the acute coronary
syndrome continuum. The Fragmin during Instability in
Coronary Artery Disease (FRISC) trial [37] noted a strong
correlation between elevation of troponins and mortality at
30 days and at 5 months. Stubbs et al [38] showed the
potential of troponin T for long-term risk stratification of
selected patients with unstable angina. During a median 3-
year follow-up period, 29% of troponin T-positive patients
versus 17% of troponin T-negative patients died or had an
MI (P = 0.07). After adjusting for revascularization, this dif-
ference reached statistical significance (P = 0.042). In the
Global Utilization of Streptokinase and t-PA for Occluded
Coronary Arteries (GUSTO)-IIa troponin substudy [39],
baseline troponin T level was a powerful, independent
marker of short-term risk. After multivariable adjustment for
CK-MB level and electrocardiographic category, baseline
troponin T level was a strong predictor of 30-day mortality
(c2 9.2; P = 0.027). This difference in mortality rates for tro-
ponin T-positive and -negative patients was maintained at 1
year (14.1% versus 4.5%; P < 0.0001) [40]. A meta-analy-
sis of several studies in over 4000 patients [41] calculated
risk ratios for death or MI for troponin T positivity of 2.7
(95% CI 2.1–3.4; P < 0.001) and for troponin I positivity of
4.2 (95% CI 2.7–6.4; P < 0.001). Still, the odds ratios
(ORs) for an adverse outcome vary substantially between
the studies.
A recently published investigation [42] refined the levels of
risk for elevated troponins in the setting of acute coronary
syndromes. A meta-analysis of a large database was con-
ducted; by considering the diversity of follow-up duration,
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Table 4
Causes for detectable serum levels of troponins
Myocardial necrosis unequivocal Myocardial necrosis possible Myocardial necrosis unclear
Myocardial infarction Myocarditis Renal failure
Cardiac surgery Heart failure Chronic haemodialysis
Coronary angioplasty Rejection of heart transplant Rhabdomyolysis (from connective-tissue 
Defibrillation Cardiac contusion diseases)
Catheter ablation Critically ill patients
Resuscitationthat analysis allowed for a more precise estimation of risk.
However, consistent with earlier studies, results showed
pooled ORs of 2.86 (95% CI 2.35–3.47; P < 0.0001) in
patients with ST-segment elevation and 4.93 (95% CI
3.77–6.45; P < 0.0001) in patients without ST-segment
elevation for the risk of cardiac death and MI at 30-day
follow up. That analysis emphasized the potential of tro-
ponins to detect myocardial micronecrosis in the absence
of ST-segment elevation and to predict heightened risk in
these patients.
ST-segment elevation myocardial infarction
In 240 patients with ST-segment elevation, Stubbs et al
[31] described higher 30-day mortality in those who had
troponin T levels greater than 0.2 ng/ml on admission
(c2 13.3; P = 0.0002). At a median 3 years of follow up,
there was nearly a fourfold difference in survival. The
Thrombolysis in Myocardial Infarction (TIMI)-IIIb substudy
[43] showed that mortality rates increase with increasing
levels of troponin I; at 42 days the mortality was 7.5% in
patients with the highest level of troponin I. In the GUSTO-
III trial [44], troponin T was measured qualitatively in
12,666 patients with ST-segment elevation who were ran-
domized to receive alteplase or reteplase. Patients with a
positive troponin T result at baseline had significantly
higher 30-day mortality than did troponin-negative patients
(15.7% versus 6.2%; P = 0.001). Troponin added inde-
pendently to the prediction of 30-day mortality, even after
adjustment for major risk factors, including symptom dura-
tion (c2 46; P = 0.001). Of particular interest is one study
that included 90-min angiography, which also assessed
baseline troponin T levels in 100 patients with acute MI
receiving aspirin and intravenous streptokinase [45]. Tro-
ponin T-positive patients (=0.1 ng/ml) were significantly
less likely to have TIMI grade 3 flow at 90 min than were
patients with a negative baseline troponin T (32% versus
62%; P = 0.01), suggesting less effective reperfusion in
those who were positive for troponin T.
Left ventricular dysfunction
Apple et al [46] reported a significant, inverse relationship
between peak troponin T values and left ventricular func-
tion as assessed by echocardiography (r = 0.46; P = 0.04).
It has also been shown that, among patients with severe
heart failure of various origin, the 18-month mortality for the
60% who were troponin T positive was significantly higher
than for troponin T-negative patients (61.1% versus 8.3%;
P = 0.0093) [47]. Thus, the troponins have some predic-
tive value in left ventricular impairment.
Troponin measurement in the emergency
department
Patients who present to the emergency room with acute
chest pain represent a heterogeneous cohort, with symp-
toms that are compatible with MI but low clinical likelihood
of significant heart disease. For clinicians, it is of particular
interest to identify those patients with an ischaemic mech-
anism of myocardial necrosis, who are known to be at
heightened risk. Accumulating data confirm the potential
role of troponins in risk stratification in chest pain cohorts
not only in the short term, but also in the long term. In
1047 patients with chest pain and electrocardiographic
evidence of ischaemia, the subset who were troponin I
positive (cutoff 0.4 ng/ml) had an adjusted OR of 1.8
(95% CI 1.1–2.9) for major cardiac events within 72 h
[48]. Using logistic regression analysis, Hamm et al [49]
showed that, even after adjustment for electrocardio-
graphic categories, either troponin T or troponin I rapid
assays made a highly significant contribution to prediction
of 30-day outcomes in patients seen in the emergency
department. Recently, it was convincingly demonstrated
[50] that positive rapid bedside troponin T assay results in
patients with suspected acute coronary syndrome
remained a strong predictor of long-term mortality (relative
risk [RR] 4.3, 95% CI 1.3–14.0). These studies particu-
larly strengthen the role of point-of-care testing, and
suggest that even a qualitative test result might be useful
for emergency medicine care givers.
Therapeutic potential in patients at troponin-
identified high risk
In patients with an acute coronary syndrome, increased
troponin levels must be regarded as a marker for
ischaemia caused by platelet activation and aggregation,
with subsequent distal embolization of thrombi leading to
necrosis. Angiographic findings strongly support the
hypothesis that troponins are surrogate markers of throm-
bus formation. Angiograms performed in the c7E3 Fab
Antiplatelet Therapy in Unstable Refractory Angina
(CAPTURE) trial [51] showed visual thrombi to be more
frequent in troponin T-positive patients (11.6% versus
4.0%; P < 0.01), and that these patients had greater
thrombus resolution and a greater reduction in clinical out-
comes after treatment with abciximab than did troponin T-
negative patients. As a result, potent antithrombotic
agents have been assessed for their ability to prevent
ischaemic events in acute coronary syndromes, especially
in troponin-positive patients.
Low-molecular-weight heparins
Among 976 patients from the FRISC trial [52], those with
troponin T levels <0.06, 0.06–0.18 and >0.18 ng/ml
during the first 24 h after admission had a 4.3, 10.5 and
16.1 risk for death or MI, respectively. Outcomes did not
differ between patients with unstable angina versus MI
among the groups. Dalteparin treatment predominantly
reduced the rate of death or MI in troponin-positive
patients, from 6.0 to 2.4% (RR 0.41, 95% CI 0.18–0.92).
This benefit was maintained at 40 (RR 0.52, 95% CI
0.32–0.83) and 150 days (RR 0.78, 95% CI 0.56–1.09).
Among high-risk patients with non-ST-segment elevation
acute coronary syndrome and negative CK-MB measures
Available online http://cvm.controlled-trials.com/content/2/2/075
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were troponin I positive (>0.1 ng/ml). Elevated troponin I
values during the first 24 h were strongly associated with
an adverse clinical outcome during 48 h and at 14 days.
Furthermore, treatment with enoxiparin conferred greater
benefit among those patients with abnormal troponin I
values, resulting in a 47% reduction (P = 0.001) in the
composite end-point (death, MI, urgent revascularization)
at 14 days.
Platelet glycoprotein IIb/IIIa receptor blockade
In patients with refractory unstable angina, abciximab
treatment reduced MI before, during and after angioplasty
[54]. More recently, the benefit of abciximab has been
shown to be greater in patients with elevated troponin T
(>0.1 ng/ml) [55]. The RR of death or nonfatal MI for
those given abciximab versus placebo was 0.32 (95% CI
0.12–0.49; P = 0.002), which was mostly attributable to a
reduced rate of MI (P < 0.001). This was not seen in tro-
ponin T-negative patients (OR 1.26, 95% CI 0.74–2.31;
P = 0.47).
Other glycoprotein IIb/IIIa receptor blockers, such as
tirofiban, have exhibited consistent reductions in death and
nonfatal MI [56]. Combination therapy with heparin plus
tirofiban in the Platelet Receptor Inhibition in Ischemic Syn-
drome Management (PRISM)-Plus trial [57] resulted in lower
peak levels of troponin T as compared with heparin alone
(5.2 ± 8.3 ng/ml versus 15.5 ± 29.1 ng/ml; P= 0.017). A
possible correlation between intracoronary thrombus and
clinical outcome was also addressed in that trial [58].
Patients with intracoronary thrombus had a significantly
higher rate of death or MI than did patients without thrombus
(19% versus 10%; P< 0.001).
A preferential benefit from glycoprotein IIb/IIIa blockade in
patients with acute coronary syndromes was recently con-
firmed in a substudy of the Platelet IIb/IIIa Antagonism for
the Reduction of Acute coronary syndrome events in a
Global Organization Network (PARAGON) B trial [59].
Treatment of troponin T-positive patients with lamifiban
yielded in a 42% reduction in death or MI (P = 0.02),
resulting in an event rate approaching that of troponin T-
negative patients. Accordingly, the heightened risk associ-
ated with elevated troponin T levels was ‘neutralized’ by
early administration of a glycoprotein IIb/IIIa blocker.
These data illustrate how a biochemical marker of height-
ened risk, resulting in application of potent antithrombotic
therapies, may be used to improve outcomes of patients
with acute coronary syndromes. However, preliminary
results from the GUSTO IV ACS trial (Simoons ML, 2000,
unpublished data) question the new concept of adminis-
tration of glycoprotein IIb/IIIa blockers in patients with
acute coronary syndromes and elevated troponin levels.
This was the first study to show that, among patients with
non-ST-segment elevation acute coronary syndrome who
were not scheduled for coronary angiography, the efficacy
of abciximab was not superior to that of placebo. This is
particularly noteworthy because the risk stratification
according to troponin status was estimated similarly to
that in other studies. A possible explanation might be that
the patients in that trial were not selected for early cardiac
catheterization, although other studies showed beneficial
effects of glycoprotein IIb/IIIa blockade in patients who did
not undergo revascularization.
Early angiography
The value of early, invasive approaches (angiography with
or without revascularization) is controversial. In the TIMI-
IIIB trial [60], mortality was greater overall in patients with
a troponin I level greater than 0.4 ng/ml (RR 1.11, 95% CI
1.05–1.17;  P = 0.016), but not in the subgroup of tro-
ponin I-positive patients who were randomly assigned to
the invasive strategy (RR 0.92, 95% CI 0.86–0.98;
P = 0.024). Data from the GUSTO-IIa substudy [61], in
which physicians were blinded to the troponin results,
show that troponin T-positive patients who underwent
revascularization had 1-year mortality similar to that in tro-
ponin T-negative patients (6.3% versus 6.2%; P = 0.78).
However, in patients who did not undergo angiography,
1-year mortality for troponin T-positive patients was sub-
stantially higher than that in troponin T-negative patients
(37% versus 11%; P = 0.001).
The suggestion that early revascularization may also
modify outcomes in patients at high risk was confirmed by
recently presented data from the FRISC-2 study. In a sub-
study [62] the influence of troponin T elevation and ST-
segment depression on the effects of an early invasive
versus noninvasive strategy was addressed in a random-
ized manner. A 29.7% reduction in incidence of death and
MI during a 1-year follow-up period was observed in tro-
ponin T-positive patients (RR 0.70, 95% CI 0.55–0.90;
P = 0.005). This was also seen when troponin T elevation
was combined with ST-segment depression at entry.
Detection of myocardial injury after
revascularization procedures
Troponins have high sensitivity for detection of minor
myocardial injury after angioplasty or atherectomy that is
strongly related to lesion morphology, side-branch occlu-
sion, dissections or severe vessel spasm, and periproce-
dural infarction. However, the prognostic value of
periprocedural myocardial damage remains elusive.
In a recent study [63] elevation in troponin I after elective
successful angioplasty, although more frequent than ele-
vation in troponin T or CK-MB, was not an important corre-
late of cardiac events during 1-year follow up (P = 0.34,
log-rank analysis). Multivariate analysis identified time of
balloon inflation (OR 9.2; P = 0.0012) and type B lesion
Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 2 Goldmann et al(OR 6.6; P = 0.013) as the most significant predictors of
troponin I elevation. The occurrence of Q-wave MI after
bypass surgery adversely affects long-term survival [64].
Although troponins possess the required specificity to dif-
ferentiate between surgical trauma to skeletal muscle and
myocardial damage, separating new episodes of
ischaemia may be difficult because troponins are
detectable in the bloodstream for relatively long periods
[12,13]. However, the serum troponin T peak level on
day 4 after cardiac surgery has been demonstrated to indi-
cate perioperative MI as indicated by the presence of new
Q waves [65], and serum troponin I levels that exceed the
concentration caused by cannulation and cardioplegia can
indicate perioperative MI with high probability [66].
Nonischaemic myocardial injury
Different causes of myocardial injury
If an ischaemic origin of the cardiac injury is unlikely, then
other causes have to be considered. Subendocardial
injury due to increased wall stress might induce a rise in
troponins in patients with congestive heart failure [67], as
do episodes of extreme hypertension, tachycardia or right
ventricular injury in patients with pulmonary embolism.
Alternatively, increase in biomarkers may occur after
severe blunt trauma to the thorax causing myocardial con-
tusion [68], or in response to severe hypotension or
release of endogenous substances in critically ill patients
(ie patients with multiple-organ dysfunction syndrome
after traumatic shock) [69,70]. Furthermore, increased
levels of troponins were observed in patients with peri-
carditis [71], suggesting involvement of the myocardium
in the inflammatory process. However, the diagnosis of
myocarditis can only be confirmed by immunohis-
tochaemical techniques. Lauer et al [72] reported
myocyte injury as detected by troponin T in 35% of
patients with immunohistologically confirmed myocarditis,
yielding a positive predictive value of 93% for the bio-
marker. The extent to which knowledge of the troponin
status could impact on medical care under these condi-
tions deserves further investigation.
Myocardial injury after heart transplantation
In noninvasive estimation of acute heart–allograft rejec-
tion, increasing troponin T levels that paralleled the sever-
ity of graft rejection were of prognostic and diagnostic
value [73]. Whether the elevation in levels of troponins
can also indicate future development of coronary artery
disease in heart transplant patients must be investigated
prospectively.
Myocardial necrosis in renal failure
Patients with end-stage renal disease are at significant risk
for major coronary events. The likelihood that dialysis
patients will die from cardiac causes has been estimated
to be approximately 20 times higher than in the general
population [74]. The clinical value of troponins to rule out
MI or to identify high-risk patients has been questioned,
because some studies have noted apparently false-posi-
tive results for troponin T in patients receiving dialysis.
Debate continues as to whether increased levels of tro-
ponin T in those patients result from re-expression of tro-
ponin T in skeletal muscle [27] or from ‘uraemic
cardiomyopathy’ with subclinical myocardial injury [75].
However, the observation of troponin T re-expression in
patients with severe renal disease was questioned by
Haller et al [75], who found no evidence for troponin T
expression in truncal skeletal muscle caused by uraemia,
which strengthens the argument for troponin T originating
from heart muscle.
Clinically, troponin T and I measures have been compared
in patients with end-stage renal failure in order to investi-
gate how the biomarkers are affected by dialysis and
whether troponins could predict prognosis in those
patients. Of note was that dialysis increased troponin T
values, but decreased troponin I values (cutoff 0.4 ng/ml)
[76]; this effect was independent of the dialysis membrane
used. In accord with previous findings, elevation of either
troponin T or I correlated with adverse cardiac outcomes.
Because second- and third-generation troponin T assays
detect only those troponin T isoforms that are expressed in
the adult human heart [28], the assumption of false-positive
results can be refuted, and clinically undetected minor
myocardial injury should be considered when troponin T
values are positive in end-stage renal disease patients.
However, several authors favour troponin I for risk stratifica-
tion of renal failure patients, and report superior prognostic
value for long-term outcome. This was not confirmed by
Van Lente et al [77], who reported reduced sensitivity and
specificity for adverse outcome in patients with renal insuf-
ficiency and suspected cardiovascular disease as
assessed using both troponin T and I (cutoffs 0.02 and
0.35 ng/ml, respectively); a case-match approach showed
no advantage of one troponin over the other.
Conclusion
Measurement of cardiac troponins has gained a leading
position in the field of biochemical diagnosis of myocardial
necrosis, as compared with conventional CK-MB mea-
surement. Data reported during the past decade have indi-
cated superior efficacy for troponins T and I in the
diagnosis of myocardial damage, which even reflect micro-
scopic zones of myocardial necrosis. According to the
new definition of MI [9], cardiac troponin (T or I) is the pre-
ferred biomarker for the routine diagnosis of MI. However,
retrospective confirmation of MI is no longer the sole role
of a cardiac marker. In patients with acute coronary syn-
dromes, troponin release must be regarded as a marker of
thrombus formation and peripheral embolization. More-
over, troponins offer the potential for early risk stratifica-
tion, greatly enhancing our ability to develop new
therapeutic approaches.
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hGiven the heterogeneity of troponin values and cutoff
points, it is not clear whether the exact magnitude of tro-
ponin elevation is essential for clinical decision making. It
appears that patients who are identified to have an ‘active
thrombotic process’ are those who would predominantly
benefit from antithrombotic treatment. Therefore,
dichotomizing patients as ‘troponin positive’ or ‘troponin
negative’ appears adequate for risk stratification, and ST-
segment depression could add further information.
However, efforts must focus on standardization of the tro-
ponin I assay in order to avoid confusion associated with
different cutoffs. Clinical laboratories must also pay careful
attention to the quality of assays, because clinicians will
now use the troponins for enhanced diagnostic and thera-
peutic decision making.
Until now, no standardized regimen has existed for the
treatment of those patients who are identified as being in
a high-risk subset in the heterogeneous population of
unstable angina patients. At least the failure of throm-
bolytic therapy to improve prognosis has been clearly
demonstrated. If it is now accepted that any amount of
myocardial necrosis caused by ischaemia should be
regarded as an infarct, then the correct way to view tro-
ponin-positive patients is that they are experiencing
momentary microinfarction. Such a change in the defini-
tion of infarction would result in a profound increase in
sensitivity and specificity of the biomarker. More patients
would be correctly identified as having MI, and fewer false-
positive results would be found.
With that knowledge, it appears even more important to
adapt treatment guidelines appropriately. At present anti-
coagulation with intravenous unfractioned heparin or sub-
cutaneous low-molecular-weight heparin is recommended,
and a platelet receptor glycoprotein IIb/IIIa antagonist
should also be administered in patients with high-risk fea-
tures or in whom a percutaneous intervention is planned.
Although these recommendations are derived from pre-
dominantly retrospective analyses, they satisfy the current
American College of Cardiology/American Heart Associa-
tion guidelines for the management of patients with unsta-
ble angina and non-ST-segment elevation MI [10].
Troponins T and I constitute the new ‘gold standard’ for
detection of myocardial necrosis and risk stratification.
Nevertheless, further prospective studies are needed for
stratification of different levels of risk and accordingly
treatment, in particular now that controversial results of
the current studies are accessible.
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